Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Sarcoma 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Melanoma 20Glioblastoma 12Neoplasms 10Breast Neoplasms 10Pancreatic Neoplasms 9Glioma 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Colonic Neoplasms 5Urinary Bladder Neoplasms 4Sarcoma 4Fallopian Tube Neoplasms 4Carcinoma 4Astrocytoma 4Oligodendroglioma 3Neoplasms, Plasma Cell 3Lung Neoplasms 3Colorectal Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Merkel Cell 3Carcinoma, Hepatocellular 3Brain Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Skin Neoplasms 2Osteosarcoma 2Neoplasm Metastasis 2

Interventions

Cyclophosphamide 45Peripheral Blood Stem Cell Transplantation 43fludarabine phosphate 42Mycophenolic Acid 30Whole-Body Irradiation 27Cyclosporine 27Busulfan 26Tacrolimus 23Antilymphocyte Serum 23Methotrexate 20Etoposide 20romidepsin 19Filgrastim 19Melphalan 16Radiotherapy 15Flow Cytometry 15Vorinostat 13Methylprednisolone 13Brentuximab Vedotin 13Lenalidomide 12Bexarotene 12mogamulizumab 11Psychiatric Rehabilitation 11Bortezomib 11Therapeutics 10Rituximab 10Gemcitabine 10fludarabine 9Polymerase Chain Reaction 9Biopsy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Cutaneous × poly ICLC × Clear all
NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

Phase 1/2 Completed
58 enrolled 24 charts
BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT02061449 2018-12-24

Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma

NYU Langone Health

Phase 1 Terminated
3 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡